NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 120

Registration Number: NCT00000810

Locations: 🇺🇸
Howard University Hosp., Div. of Infectious Diseases, ACTU, Washington, District of Columbia, United States
🇺🇸
Stanford CRS, Stanford, California, United States
🇺🇸
SUNY - Buffalo, Erie County Medical Ctr., Buffalo, New York, United States

and more 7 locations

A Study of Dideoxycytidine Plus Zidovudine (AZT) in HIV-Infected Children Who Have Taken AZT

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 180

Registration Number: NCT00001032

Locations: 🇺🇸
The Children's Hosp. of Philadelphia IMPAACT CRS, Philadelphia, Pennsylvania, United States
🇺🇸
Univ. of Illinois College of Medicine at Chicago, Dept. of Peds., Chicago, Illinois, United States
🇺🇸
Chicago Children's CRS, Chicago, Illinois, United States

and more 44 locations

A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 36

Registration Number: NCT00001053

Locations: 🇺🇸
Univ. of Rochester AVEG, Rochester, New York, United States

Evaluation of the Interaction Between Acetaminophen and Zidovudine

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 10

Registration Number: NCT00000731

Locations: 🇺🇸
Univ of Pittsburgh Med School, Pittsburgh, Pennsylvania, United States

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 150

Registration Number: NCT00000847

Locations: 🇺🇸
UAB AVEG, Birmingham, Alabama, United States
🇺🇸
JHU AVEG, Baltimore, Maryland, United States
🇺🇸
St. Louis Univ. School of Medicine AVEG, Saint Louis, Missouri, United States

and more 3 locations

A Trial of Alternating 2',3'-Dideoxycytidine and Zidovudine in the Treatment of Patients With Advanced HIV Disease

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 96

Registration Number: NCT00000719

Locations: 🇺🇸
Univ. of Miami AIDS CRS, Miami, Florida, United States
🇺🇸
University of Minnesota, ACTU, Minneapolis, Minnesota, United States
🇺🇸
USC CRS, Los Angeles, California, United States

and more 4 locations

Evaluation of the Interaction Between Low Dose Sulfamethoxazole-Trimethoprim and Zidovudine

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 10

Registration Number: NCT00000732

Locations: 🇺🇸
Univ of Pittsburgh Med School, Pittsburgh, Pennsylvania, United States

A Controlled Trial Comparing the Efficacy of Aerosolized Pentamidine and Parenteral/Oral Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia in AIDS

Phase 3

Completed

Conditions: Pneumonia, Pneumocystis Carinii
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 240

Registration Number: NCT00000715

Locations: 🇺🇸
Harvard (Massachusetts Gen Hosp), Boston, Massachusetts, United States
🇺🇸
Julio Arroyo, West Columbia, South Carolina, United States
🇺🇸
Bronx Municipal Hosp Ctr/Jacobi Med Ctr, Bronx, New York, United States

and more 6 locations

Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma

Phase 1

Completed

Conditions: Lymphoma, Non-Hodgkin
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 18

Registration Number: NCT00000689

Locations: 🇺🇸
USC CRS, Los Angeles, California, United States

Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients

Phase 2

Completed

Conditions: Toxoplasmosis, Cerebral
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 150

Registration Number: NCT00000643

Locations: 🇺🇸
Harbor-UCLA Med. Ctr. CRS, Torrance, California, United States
🇺🇸
Northwestern University CRS, Chicago, Illinois, United States
🇺🇸
Rush Univ. Med. Ctr. ACTG CRS, Chicago, Illinois, United States

and more 21 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy